Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Colombat

Showing results (101-110 of 114) with videos related to

Pageof 12
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2012
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphomaF Morschhauser, C Recher, N Milpied, et al.
Blood|September 10, 1998
Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's diseaseM André, M Henry-Amar, D Blaise, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 12, 2012
Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-upP Colombat, N Brousse, G Salles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 6, 2000
Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapyC Linassier, C Barin, G Calais, et al.
Blood|August 15, 1996
Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter studyE Solary, B Witz, D Caillot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de MoelleM André, M Henry-Amar, J L Pico, et al.
Bulletin Du Cancer|November 12, 2009
[Setting up supportive care in oncology: reflexions and suggestions.]P Colombat, S Antoun, R Aubry, et al.
Bone Marrow Transplantation|June 12, 2002
Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapyS Vigouroux, N Milpied, J M Andrieu, et al.
Bone Marrow Transplantation|June 18, 2013
The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMTS P Robinson, C Canals, J J Luang, et al.
Blood|January 3, 2001
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluationP Colombat, G Salles, N Brousse, et al.
Pageof 12

Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2012
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphomaF Morschhauser, C Recher, N Milpied, et al.
Blood|September 10, 1998
Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's diseaseM André, M Henry-Amar, D Blaise, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 12, 2012
Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-upP Colombat, N Brousse, G Salles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 6, 2000
Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapyC Linassier, C Barin, G Calais, et al.
Blood|August 15, 1996
Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter studyE Solary, B Witz, D Caillot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de MoelleM André, M Henry-Amar, J L Pico, et al.
Bulletin Du Cancer|November 12, 2009
[Setting up supportive care in oncology: reflexions and suggestions.]P Colombat, S Antoun, R Aubry, et al.
Bone Marrow Transplantation|June 12, 2002
Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapyS Vigouroux, N Milpied, J M Andrieu, et al.
Bone Marrow Transplantation|June 18, 2013
The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMTS P Robinson, C Canals, J J Luang, et al.
Blood|January 3, 2001
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluationP Colombat, G Salles, N Brousse, et al.
Pageof 12